Silverarc Capital Management as of March 31, 2021
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 89 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aclaris Therapeutics (ACRS) | 4.6 | $8.5M | 337k | 25.20 | |
| Curis Com New | 3.9 | $7.1M | 629k | 11.32 | |
| Vericel (VCEL) | 3.7 | $6.8M | 122k | 55.55 | |
| Insmed Com Par $.01 (INSM) | 3.5 | $6.5M | 191k | 34.06 | |
| Amryt Pharma Sponsored Ads | 3.3 | $6.0M | 430k | 13.93 | |
| ImmunoGen | 3.2 | $5.9M | 729k | 8.10 | |
| Research Alliance Corp Ii Com Cl A | 2.8 | $5.1M | 500k | 10.25 | |
| Dicerna Pharmaceuticals | 2.8 | $5.1M | 200k | 25.57 | |
| Merus N V (MRUS) | 2.8 | $5.1M | 245k | 20.89 | |
| Horizon Therapeutics Pub L SHS | 2.4 | $4.5M | 49k | 92.05 | |
| Intra Cellular Therapies (ITCI) | 2.4 | $4.4M | 130k | 33.93 | |
| Halozyme Therapeutics (HALO) | 2.4 | $4.4M | 105k | 41.69 | |
| Biogen Idec Call Option (BIIB) | 2.3 | $4.2M | 15k | 279.80 | |
| Medicus Sciences Acquisition Unit 99/99/9999 | 2.2 | $4.0M | 407k | 9.85 | |
| Affimed Therapeutics B V | 2.2 | $4.0M | 502k | 7.91 | |
| Aldeyra Therapeutics (ALDX) | 2.1 | $3.8M | 322k | 11.88 | |
| Morphic Hldg (MORF) | 2.1 | $3.8M | 60k | 63.28 | |
| Jounce Therapeutics | 2.0 | $3.6M | 350k | 10.27 | |
| Renalytix Ai Ads (RNLXY) | 1.9 | $3.5M | 135k | 25.66 | |
| Tcr2 Therapeutics Inc cs | 1.9 | $3.4M | 155k | 22.08 | |
| Biohaven Pharmaceutical Holding | 1.9 | $3.4M | 50k | 68.36 | |
| Veracyte (VCYT) | 1.8 | $3.2M | 60k | 53.75 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.7 | $3.0M | 300k | 10.16 | |
| Verastem | 1.6 | $3.0M | 1.2M | 2.47 | |
| Salarius Pharmaceuticals Com New | 1.6 | $2.9M | 2.0M | 1.48 | |
| Chemocentryx | 1.6 | $2.9M | 56k | 51.24 | |
| Larimar Therapeutics (LRMR) | 1.5 | $2.8M | 192k | 14.61 | |
| Adamas Pharmaceuticals | 1.4 | $2.5M | 523k | 4.80 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.3 | $2.4M | 19k | 128.86 | |
| Helix Acquisition Corp Com Cl A | 1.3 | $2.3M | 229k | 10.21 | |
| Sierra Oncology Com New | 1.3 | $2.3M | 135k | 17.23 | |
| Kura Oncology (KURA) | 1.2 | $2.3M | 80k | 28.27 | |
| Essa Pharma Com New (EPIX) | 1.2 | $2.1M | 74k | 29.05 | |
| Seres Therapeutics (MCRB) | 1.1 | $2.1M | 100k | 20.59 | |
| Scholar Rock Hldg Corp (SRRK) | 1.0 | $1.8M | 36k | 50.66 | |
| Oncorus | 1.0 | $1.8M | 130k | 13.92 | |
| Deciphera Pharmaceuticals | 1.0 | $1.8M | 40k | 44.84 | |
| Cyclacel Pharmaceuticals | 1.0 | $1.8M | 250k | 7.11 | |
| Evogene SHS | 1.0 | $1.8M | 350k | 5.04 | |
| Odonate Therapeutics Ord | 0.9 | $1.7M | 500k | 3.42 | |
| Arvinas Ord (ARVN) | 0.9 | $1.7M | 25k | 66.09 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 0.9 | $1.6M | 7.5k | 214.93 | |
| Turning Point Therapeutics I | 0.9 | $1.6M | 17k | 94.62 | |
| Guardant Health (GH) | 0.8 | $1.6M | 10k | 152.67 | |
| Sage Therapeutics Call Option (SAGE) | 0.8 | $1.5M | 20k | 74.85 | |
| Coherus Biosciences (CHRS) | 0.8 | $1.5M | 100k | 14.61 | |
| Fulcrum Therapeutics (FULC) | 0.8 | $1.4M | 121k | 11.78 | |
| Arena Pharmaceuticals Com New | 0.8 | $1.4M | 20k | 69.40 | |
| Polypid SHS | 0.7 | $1.4M | 150k | 9.16 | |
| Kalvista Pharmaceuticals (KALV) | 0.7 | $1.3M | 50k | 25.70 | |
| 89bio (ETNB) | 0.6 | $1.2M | 50k | 23.68 | |
| Cogent Biosciences (COGT) | 0.6 | $1.1M | 120k | 8.78 | |
| Cellectar Biosciences Com Par | 0.5 | $976k | 606k | 1.61 | |
| Akero Therapeutics (AKRO) | 0.5 | $928k | 32k | 29.00 | |
| United Therapeutics Corporation (UTHR) | 0.5 | $897k | 5.4k | 167.23 | |
| Mirati Therapeutics | 0.5 | $857k | 5.0k | 171.40 | |
| Immunovant (IMVT) | 0.4 | $808k | 50k | 16.03 | |
| Iveric Bio | 0.4 | $804k | 130k | 6.18 | |
| Wave Life Sciences SHS (WVE) | 0.4 | $784k | 140k | 5.60 | |
| Surface Oncology | 0.4 | $780k | 100k | 7.80 | |
| Seagen | 0.4 | $694k | 5.0k | 138.80 | |
| Kala Pharmaceuticals | 0.4 | $689k | 102k | 6.74 | |
| Compugen Ord (CGEN) | 0.4 | $644k | 75k | 8.59 | |
| Trillium Therapeutics Com New | 0.4 | $644k | 60k | 10.73 | |
| Otonomy | 0.3 | $640k | 251k | 2.55 | |
| Aptose Biosciences Com New | 0.3 | $598k | 100k | 5.98 | |
| Mereo Biopharma Group Ads (MREO) | 0.3 | $590k | 175k | 3.37 | |
| Leap Therapeutics | 0.3 | $570k | 300k | 1.90 | |
| Biolinerx Sponsored Ads (BLRX) | 0.3 | $558k | 200k | 2.79 | |
| Travere Therapeutics (TVTX) | 0.3 | $499k | 20k | 24.95 | |
| Delcath Sys Com New (DCTH) | 0.3 | $497k | 40k | 12.43 | |
| Immatics SHS (IMTX) | 0.3 | $469k | 42k | 11.22 | |
| Miragen Therapeutics (VRDN) | 0.3 | $461k | 28k | 16.71 | |
| Syndax Pharmaceuticals (SNDX) | 0.2 | $447k | 20k | 22.35 | |
| Rocket Pharmaceuticals (RCKT) | 0.2 | $444k | 10k | 44.40 | |
| Medicenna Therapeutics Corp. (MDNAF) | 0.2 | $439k | 108k | 4.08 | |
| Therapeutics Acquisition Cor Com Cl A | 0.2 | $420k | 40k | 10.50 | |
| Mersana Therapeutics (MRSN) | 0.2 | $405k | 25k | 16.20 | |
| Actinium Pharmaceuticals (ATNM) | 0.2 | $350k | 46k | 7.62 | |
| Ardelyx (ARDX) | 0.2 | $298k | 45k | 6.62 | |
| Prometheus Biosciences | 0.1 | $274k | 15k | 18.27 | |
| Viracta Therapeutics (VIRX) | 0.1 | $264k | 29k | 9.24 | |
| Gamida Cell SHS | 0.1 | $189k | 23k | 8.08 | |
| Soleno Therapeutics Com New | 0.1 | $158k | 125k | 1.26 | |
| Black Diamond Therapeutics (BDTX) | 0.1 | $146k | 6.0k | 24.33 | |
| Pieris Pharmaceuticals | 0.1 | $129k | 50k | 2.58 | |
| Chardan Healthcare Acqu- Ord | 0.1 | $98k | 14k | 7.12 | |
| Chardan Healthcr Acqstn 2 *w Exp 03/05/202 | 0.1 | $93k | 99k | 0.94 | |
| Calithera Biosciences | 0.0 | $73k | 30k | 2.43 |
